Back to results
US 2021/0268027 A1Published application
Chimeric antigen receptors targeting cd37 and cd19
AssigneeThe General Hospital Corporation
InventorMarcela V. Maus
Life of this patent
Estimating the term…
Abstract
The invention provides bispecific chimeric antigen receptors (CARs) targeting CD37 and CD19, as well as related molecules, immune cells including the same, compositions thereof, and their methods of use. The invention further provides methods for treating a disease or disorder, e.g., a cancer.
Claims40
A chimeric antigen receptor (CAR) comprising (i) an extracellular domain comprising a CD37-binding domain and a CD19-binding domain, (ii) a transmembrane domain, and (iii) an intracellular signaling domain.
Dependencies are inferred from the claim text.